Actos Bladder Cancer Trial Begins This Week

The first trial of many lawsuits alleging that diabetes medication Actos causes bladder cancer is scheduled to begin this week in Los Angeles.
Feb. 21, 2013 - PRLog -- The first trial of many lawsuits alleging that diabetes medication Actos causes bladder cancer is scheduled to begin this week in Los Angeles.  The case Cooper v. Takeda Pharmaceuticals, Inc., CGC-12-518535 contends that Actos manufacturer, Takeda, failed to warn consumers that Actos could cause bladder cancer. Plaintiff, Jack Cooper, who is gravely ill, took Actos for more than two years and was diagnosed with bladder cancer in November 2011.  This trial comes just a month after Takeda received regulatory approval for Nesina, a new diabetes drug to replace Actos, which went off of patent protection last year. Actos was previously the world’s top-selling diabetes drug.

   Takeda is now facing more than 3,000 lawsuits claiming Actos caused bladder cancer or other health problems. Sales of Actos reached $4.5 billion in 2011 and accounted for 27 percent of Takeda’s revenue at that time according to Bloomberg. More than 1,200 lawsuits have been consolidated before the Honorable Rebecca Doherty in the U.S. District Court for the Western District of Louisiana. The first federal trial is scheduled to start on November 3, 2014.

   Takeda officials are defending Actos, claiming that the U.S. Food and Drug Administration (FDA) found it to be a safe and effective drug.  Further, the company claims that studies do not establish a causal link between Actos and bladder cancer, according to Takeda attorney, D’Lesli Davis.  However, in 2011, FDA officials found that an analysis of a company-sponsored study showed some Actos users faced an increased risk of developing bladder cancer or cardiac issues and ordered Takeda to add new warnings to its label. 1 Takeda has pulled the drug off of the markets in Germany and France due to its association with bladder cancer.

   Plaintiffs contend that Takeda employees knew about Actos’ link to bladder cancer even before the company won approval for use in the United States in 1999.  Plaintiffs assert that Takeda executives resisted FDA requests to add bladder-cancer warnings to Actos’s label for years in order to protect the drug’s profits.  Takeda steadfastly maintains that there is no causal link between Actos and bladder cancer.  However, a recent study published in the British Diabetic Association journal, “Diabetic Medicine,” has confirmed an association between Actos and bladder cancer.  The article analyzed six separate Actos studies involving over 215,142 Actos users who were followed for an average of 44 months.  The risk of bladder cancer was significantly higher in patients using Actos. 2 The British Medical Journal also concluded that taking Actos for two years can double the risk of developing bladder cancer. 3 An additional study in the Canadian Medical Association Journal in July 2012 noted that patients taking Actos incur a 22 percent increased risk of developing bladder cancer. 4  

   Ennis & Ennis, P.A. continues to offer free, nationwide, confidential consultations to anyone who was injured Actos by calling toll free 1-800-856-6405 or by going to and completing an online case evaluation form. Actos users developing bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering and more.


Email:*** Email Verified
Tags:Actos, Trial, Injury, Ennis
Location:Fort Lauderdale - Florida - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Ennis & Ennis, P.A. PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share